Human Pathology
Volume 41, Issue 2 , Pages 262-270 , February 2010

p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy

  • Takahiro Hasebe, MD, PhD

      Affiliations

    • Clinical Trials and Practice Support Division, Pathology Consultation Service, Center for Cancer Control and Information Services, National Cancer Center, Tokyo 104-0045, Japan
    • Corresponding Author InformationCorresponding author.
    • ,
  • Nobuko Tamura, MD

      Affiliations

    • Department of Breast Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan
    • ,
  • Nao Okada, MD

      Affiliations

    • Department of Breast Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan
    • ,
  • Takashi Hojo, MD

      Affiliations

    • Department of Breast Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan
    • ,
  • Sadako Akashi-Tanaka, MD, PhD

      Affiliations

    • Department of Breast Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan
    • ,
  • Chikako Shimizu, MD

      Affiliations

    • Division of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
    • ,
  • Histoshi Tsuda, MD, PhD

      Affiliations

    • Clinical Laboratory Division, National Cancer Center Hospital, Tokyo 104-0045, Japan
    • ,
  • Tatsuhiro Shibata, MD, PhD

      Affiliations

    • Cancer Genomics Project, National Cancer Center Research Institute, Tokyo 104-0045, Japan
    • ,
  • Yuko Sasajima, MD, PhD

      Affiliations

    • Clinical Laboratory Division, National Cancer Center Hospital, Tokyo 104-0045, Japan
    • ,
  • Motoki Iwasaki, MD, PhD

      Affiliations

    • Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo 104-0045, Japan
    • ,
  • Takayuki Kinoshita, MD, PhD

      Affiliations

    • Department of Breast Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan

Received 10 April 2009 ,Revised 27 July 2009 ,Accepted 30 July 2009.

References 

  1. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–527
  2. Sheehan KM, Gulmann C, Eichler GS, et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene. 2008;27:323–331
  3. Singer CF, Gschwantler-Kaulich D, Fink-Retter A, et al. Differential gene expression profile in breast cancer–derived stromal fibroblasts. Breast Cancer Res Treat. 2008;110:273–281
  4. Loussouarn D, Campion L, Sagan C, et al. Prognostic impact of syndecan-1 expression in invasive ductal carcinomas. Br J Cancer. 2008;98:1993–1998
  5. Studebaker AW, Storci G, Werbeck JL, et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6–dependent manner. Cancer Res. 2008;68:9087–9095
  6. Hasebe T, Sasaki S, Imoto S, et al. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol. 2000;156:1701–1710
  7. Hasebe T, Sasaki S, Imoto S, et al. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol. 2001;14:325–337
  8. Moinfar F, Man YG, Arnould L, et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implication for tumorigenesis. Cancer Res. 2000;60:2562–2566
  9. Patocs A, Zhang L, Xu Y, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007;357:2543–2551
  10. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer. 1957;11:359–377
  11. Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node–positive breast cancer: a 10-year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol. 1993;11:1929–1935
  12. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat. 1998;49:195–208
  13. Hasebe T, Sasaki S, Imoto S, et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol. 2002;15:502–516
  14. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer. 1977;40:574–587
  15. Fisher B. Adjuvant chemotherapy in the primary management of breast cancer. Med Clin North Am. 1977;61:953–965
  16. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–206
  17. Allred DC, Harvey JM, Berardo MD, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–168
  18. Mohsin S, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–1554
  19. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473–2481
  20. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43
  21. Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003;88:406–412
  22. Taucher S, Rudas M, Mader RM, et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat. 2003;82:207–213
  23. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005;446:489–496
  24. Wang J, Buchholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer. 2002;94:3107–3114
  25. von Minckwitz G, Sinn HP, Raab G, et al. Clinical response after two cycle compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathologic complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008;10:R30
  26. Sullivan PS, Apple SK. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?. Breast J. 2009;15:146–154
  27. Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer. 2008;122:534–546
  28. Dudley AC, Shin SC, Cliffe AR, et al. Attenuated p53 activation in tumor-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer. 2008;99:118–125
  29. Lafkas D, Timis G, Papavassiliou AG, et al. p53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Int J Cancer. 2008;123:967–971
  30. Bierie B, Moses HL. Under pressure: stromal fibroblasts change their ways. Cell. 2005;123:985–987
  31. Hill R, Song Y, Cardiff RD, et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2006;123:1001–1011
  32. Kiaris H, Chatzistamou I, Trimis G, et al. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. 2005;65:1627–1630
  33. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenviroment in breast cancer. Cancer Cell. 2004;6:17–32
  34. Lebret SC, Newgreen DF, Thompson EW, et al. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res. 2007;9:R19
  35. Campbell IG, Qiu W, Polyak K, et al. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;10:1634–1635
  36. Baak JP, Colpaert CG, van Diest PJ, et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer. 2005;41:2093–2101
  37. Colpaert C, Vermeulen PB, van Beest P, et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node–negative breast cancer patients. Histopathology. 2001;39:416–425

☆ This study was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI) (C) (19590378, 21590393) from Japan Society for the Promotion of Science and in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare (20-16) of Japan.

PII: S0046-8177(09)00284-6

doi: 10.1016/j.humpath.2009.07.021

Human Pathology
Volume 41, Issue 2 , Pages 262-270 , February 2010

Article Tools

* Image Usage & Resolution